Topic - Novartis Pharmaceuticals Corp.

Subscribe to this topic via RSS or ATOM
Related Stories
  • Dr. Jerome Kassirer, a professor at Tufts Medical School

    Drug firm hired athletes, luring doctors to play ball

    Pharmaceutical companies no longer court doctors with tickets to sporting events and lavish trips, but one of the nation's largest drug manufacturers deployed a squad of sports figures to get physicians to play ball.

  • Novartis to pay more than $400M in penalties

    Novartis Pharmaceuticals Corp. will plead guilty to charges it marketed an epilepsy medicine for unapproved uses and pay $422.5 million in civil and criminal penalties, federal officials announced Thursday.

  • Novartis to pay $422.5 million over marketing

    Novartis Pharmaceuticals Corp. has agreed to pay $422.5 million stemming from illegal marketing of the anti-epileptic drug Trileptal and five other drugs, the Justice Department announced Thursday.

  • Feds: Novartis to pay more than $400M in penalties

    Novartis Pharmaceuticals Corp. will plead guilty to charges it marketed an epilepsy medicine for unapproved uses and pay $422.5 million in civil and criminal penalties, federal officials announced Thursday.

  • U.S. Attorney Zane David Memeger smiles after speaking during a news conference about Novartis Pharmaceuticals Corp., Thursday, Sept. 30, 2010, in Philadelphia. The U.S. Justice Department says the pharmaceutical maker has agreed to pay $422.5 million stemming from illegal marketing of the anti-epileptic drug Trileptal and five other drugs. (AP Photo/Matt Slocum)

    Novartis fined $422.5M in marketing, kickback case

    Novartis Pharmaceuticals Corp. will pay $422.5 million in penalties for marketing an epilepsy medicine for unapproved uses and for paying kickbacks to doctors to prescribe it and five other drugs, federal officials announced Thursday.

More Stories →

Happening Now